BACKGROUND Liquid biopsies that are based on analysis of cell-free DNA from plasma
offer diagnostic information that is otherwise accessible conventionally through invasive …

Pancreatic cancer is a highly malignant digestive system tumor with a poor prognosis. Most
pancreatic cancer patients are diagnosed at an advanced stage or even metastasis due to …

Biomarker discovery and validation are necessary for improving the prediction of clinical
outcomes and patient monitoring. Despite considerable interest in biomarker discovery and …

Markers are needed to facilitate early detection of pancreatic ductal adenocarcinoma
(PDAC), which is often diagnosed too late for effective therapy. Starting with a PDAC cell …

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease for a multitude of
reasons including very late diagnosis. This in part is due to the lack of understanding of the …

Pancreatic cancer is currently the most lethal tumor entity and case numbers are rising. It will
soon be the second most frequent cause of cancer-related death in the Western world …

Cell-free DNA (cfDNA) in human plasma provides access to molecular information about the
pathological processes in the organs or tumors from which it originates. These DNA …

Disruption of the epigenetic program of gene expression is a hallmark of cancer that initiates
and propagates tumorigenesis. Altered DNA methylation, histone modifications and ncRNAs …

Epigenetic alterations play a key role in the initiation and progression of cancer. Therefore, it
is possible to use epigenetic marks as biomarkers for predictive and precision medicine in …

Immunotherapies are revolutionizing the clinical management of a wide range of cancers.
However, intrinsic or acquired unresponsiveness to immunotherapies does occur due to the …